Adult T-cell leukemia/lymphoma treatment in Bahia, Brazil

Pedro Dantas Oliveira , Ítala Gomes , Victor Hugo Gomes Souza , Ernesto Cunha Pires , Glória Bomfim Arruda , Achiléa Bittencourt
{"title":"Adult T-cell leukemia/lymphoma treatment in Bahia, Brazil","authors":"Pedro Dantas Oliveira ,&nbsp;Ítala Gomes ,&nbsp;Victor Hugo Gomes Souza ,&nbsp;Ernesto Cunha Pires ,&nbsp;Glória Bomfim Arruda ,&nbsp;Achiléa Bittencourt","doi":"10.1016/j.bjhh.2016.09.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Adult T-cell leukemia/lymphoma is a peripheral disease associated with human T-cell lymphotropic virus type 1. Treatment is carried out according to clinical type with watchful waiting being recommended for less aggressive types. Aggressive adult T-cell leukemia/lymphoma is generally treated with chemotherapy and/or antivirals. The objective of this study was to correlate the survival of patients diagnosed in Bahia, Brazil, with the therapeutic approaches employed and to evaluate what issues existed in their treatment processes.</p></div><div><h3>Methods</h3><p>Eighty-three adult T-cell leukemia/lymphoma patients (26 smoldering, 23 chronic, 16 acute, 13 lymphoma and five primary cutaneous tumoral) with available data were included in this study.</p></div><div><h3>Results</h3><p>Complete response was achieved in seven smoldering patients with symptomatic treatment, in two with chronic disease using antivirals/chemotherapy, in one with acute disease using antivirals and in one lymphoma using the LSG15 regimen [vincristine, cyclophosphamide, doxorubicin, and prednisolone (VCAP); doxorubicin, ranimustine, and prednisolone (AMP); and vindesine, etoposide, carboplatin, and prednisolone (VECP)]. Smoldering patients who received symptomatic treatment presented longer survival. Favorable chronic patients treated with antivirals presented longer survival compared to the unfavorable subtype. However, for the acute form, first-line chemotherapy was better, albeit without significance, than antivirals. Only one of the patients with lymphoma and primary cutaneous tumors responded.</p></div><div><h3>Conclusions</h3><p>Watchful waiting associated with phototherapy represents the best option for smoldering adult T-cell leukemia/lymphoma with survival in Bahia being superior to that described in Japan. There was a trend of better results with zidovudine/interferon-alpha in favorable chronic disease. Excellent results were achieved in the lymphoma type treated with the LSG15 protocol. Patients are diagnosed late probably due to lack of knowledge of adult T-cell leukemia/lymphoma by primary healthcare doctors and a Brazilian treatment protocol needs to be established.</p></div>","PeriodicalId":21233,"journal":{"name":"Revista Brasileira de Hematologia e Hemoterapia","volume":"39 1","pages":"Pages 13-19"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bjhh.2016.09.012","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Brasileira de Hematologia e Hemoterapia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1516848416301141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Background

Adult T-cell leukemia/lymphoma is a peripheral disease associated with human T-cell lymphotropic virus type 1. Treatment is carried out according to clinical type with watchful waiting being recommended for less aggressive types. Aggressive adult T-cell leukemia/lymphoma is generally treated with chemotherapy and/or antivirals. The objective of this study was to correlate the survival of patients diagnosed in Bahia, Brazil, with the therapeutic approaches employed and to evaluate what issues existed in their treatment processes.

Methods

Eighty-three adult T-cell leukemia/lymphoma patients (26 smoldering, 23 chronic, 16 acute, 13 lymphoma and five primary cutaneous tumoral) with available data were included in this study.

Results

Complete response was achieved in seven smoldering patients with symptomatic treatment, in two with chronic disease using antivirals/chemotherapy, in one with acute disease using antivirals and in one lymphoma using the LSG15 regimen [vincristine, cyclophosphamide, doxorubicin, and prednisolone (VCAP); doxorubicin, ranimustine, and prednisolone (AMP); and vindesine, etoposide, carboplatin, and prednisolone (VECP)]. Smoldering patients who received symptomatic treatment presented longer survival. Favorable chronic patients treated with antivirals presented longer survival compared to the unfavorable subtype. However, for the acute form, first-line chemotherapy was better, albeit without significance, than antivirals. Only one of the patients with lymphoma and primary cutaneous tumors responded.

Conclusions

Watchful waiting associated with phototherapy represents the best option for smoldering adult T-cell leukemia/lymphoma with survival in Bahia being superior to that described in Japan. There was a trend of better results with zidovudine/interferon-alpha in favorable chronic disease. Excellent results were achieved in the lymphoma type treated with the LSG15 protocol. Patients are diagnosed late probably due to lack of knowledge of adult T-cell leukemia/lymphoma by primary healthcare doctors and a Brazilian treatment protocol needs to be established.

Abstract Image

巴西巴伊亚州成人t细胞白血病/淋巴瘤的治疗
成人t细胞白血病/淋巴瘤是一种与人t细胞嗜淋巴病毒1型相关的外周疾病。根据临床类型进行治疗,对侵袭性较弱的类型建议观察等待。侵袭性成人t细胞白血病/淋巴瘤通常用化疗和/或抗病毒药物治疗。本研究的目的是将巴西巴伊亚确诊的患者的生存率与所采用的治疗方法相关联,并评估其治疗过程中存在的问题。方法收集83例成人t细胞白血病/淋巴瘤患者(阴发性26例,慢性23例,急性16例,淋巴瘤13例,原发性皮肤肿瘤5例)。结果7例经对症治疗的阴排患者获得完全缓解,2例慢性疾病患者使用抗病毒药物/化疗,1例急性疾病患者使用抗病毒药物,1例淋巴瘤患者使用LSG15方案[长春新碱、环磷酰胺、阿霉素和强的松龙(VCAP)];阿霉素、雷莫司汀和强的松龙(AMP);长春地辛、依托泊苷、卡铂和强的松龙(VECP)]。接受对症治疗的阴燃患者存活时间较长。接受抗病毒药物治疗的有利慢性患者比不利亚型患者的生存时间更长。然而,对于急性形式,一线化疗优于抗病毒药物,尽管没有显著性。只有1例淋巴瘤和原发性皮肤肿瘤患者有反应。结论观察等待联合光疗是治疗阴燃成人t细胞白血病/淋巴瘤的最佳选择,巴伊亚的生存率优于日本。齐多夫定/干扰素治疗有利的慢性疾病有更好的结果趋势。在使用LSG15方案治疗的淋巴瘤类型中取得了极好的结果。由于初级保健医生缺乏对成人t细胞白血病/淋巴瘤的知识,患者诊断较晚,需要建立巴西治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
21 weeks
期刊介绍: A Revista Brasileira de Hematologia e Hemoterapia é um periódico científico de propriedade da Associação Brasileira de Hematologia e Hemoterapia, publicada bimestralmente. A abreviatura de seu título é Rev. Bras. Hematol. Hemoter., que deve ser usada em bibliografias, notas de rodapé e em referências e legendas bibliográficas.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信